Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative Site-specific N-glycosylation Analysis Reveals the Signatures of Urinary Uromodulin in Patients with Renal Calcium Oxalate Stones

ABSTRACT: Abnormal N-glycosylation of uromodulin (Umod, also known as Tamm-Horsfall protein) has been implicated in the pathogenesis of various urinary system diseases. However, the site-specific N-glycosylation patterns of urinary Umod in healthy controls (HCs) versus those with kidney stones (KSs) have yet to be detailed. In this study, we isolated and purified Umod from the urine of 24 patients with calcium oxalate (CaOx) KSs and 24 HCs using a refined diatomaceous earth adsorption method. After digestion with trypsin and Glu-C, intact N-glycopeptides (IGPs) were enriched via hydrophilic interaction liquid chromatography (HILIC) and analyzed via EThcD-sceHCD-MS/MS. Data processing was conducted using Byonic and PANDA software. A total of 700 IGPs, 8 N-glycosites, and 145 N-glycans were identified, marking the most extensive identification of N-glycosylation in Umod to date. Through quantitative and site-specific N-glycosylation analyses, the study found 39 IGPs to be up-regulated (p<0.05, FC>1.5) and 60 down-regulated IGPs (p<0.05, FC<0.67) in KS groups. Additionally, the analysis of N-glycan composition and site-specific N-glycosylation highlighted KS-specific N-glycosylation modifications. Overall, these results suggest that variations in Umod N-glycosylation may critically contribute to the formation of CaOx kidney stones by modulating its function.

ORGANISM(S): Homo Sapiens

SUBMITTER: Yong Zhang

PROVIDER: PXD068648 | iProX | Sat Sep 20 00:00:00 BST 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Pressure Cycling Technology-Based Quantitative Glycoproteomics Reveals Distinctive N‑glycosylation Patterns in Human Kidney Tissues with Minor Glomerular Abnormalities

Project description:Kidney diseases present substantial clinical challenges, with aberrant glycoprotein emerging as a key pathogenic driver. Minor glomerular abnormalities (MGAs), a category of unclassified glomerular lesions defined by subtle structural changes, are commonly detected in patients with persistent, asymptomatic, isolated proteinuria or microhematuria., yet their site-specific N-glycosylation patterns remain unelucidated. To address this gap, we applied a laboratory-developed pressure cycling technology (PCT)-based quantitative glycoproteomics workflow (GlycoPCT) to compare intact N-glycopeptides (IGPs) between distant non-neoplastic tissues (DNT; n=24) and trace renal biopsy samples from MGA patients (n=27). Integrated with high-sensitivity, high-resolution mass spectrometry (EThcD-sceHCD-MS/MS), GlycoPCT identified 672 upregulated IGPs (FC>1.5, p<0.05) and 573 downregulated IGPs (FC<0.67, p<0.05) in MGA tissues. Total fucosylation type N-glycans were significantly downregulated (p<0.05), while sialylation type N-glycans were markedly downregulated (p<0.001). Additionally, 24 glycoproteins associated with the PI3K-Akt signaling pathway (a well-documented mediator of renal injury) showed broadly N-glycosylation upregulation. Site-specific N-glycosylation analysis further revealed differential patterns in IgG subclasses and complement-related markers that distinguish MGA from DNT, offering new mechanistic insights into MGA pathogenesis. These novel glyco-signatures clarify the role of N-glycosylation in renal disease, highlight TINAGL1, IgG, IgM, and complement-related glycoproteins as potential MGA biomarkers, and validate GlycoPCT as a powerful tool for trace tissue analysis. This study lays the groundwork for translating N-glycosylation findings into clinical applications to improve MGA diagnosis and management.

2025-10-21 | PXD069708 |

GlycoPCT: quantitative glycoproteomics based on pressure cycling technology reveals distinctive N-glycosylation in human liver with non-alcoholic fatty liver disease

Project description:Protein N-glycosylation plays a crucial role in the human liver, impacting key functions like hepatocyte lipid metabolism hepatocyte apoptosis, and inflammatory response. Despite its significance, the site-specific N-glycosylation patterns and their variations of liver biosy samples between healthy individuals and those with non-alcoholic fatty liver disease (NAFLD) have not been fully revealed. To address this issue, we presented a quantitative glycoproteomics called GlycoPCT based on pressure cycling technology. This method allows for the efficient recovery of intact N-glycopeptides (IGPs) and provides a thorough and accurate quantitative analysis of trace liver biopsy samples. Our research uncovered a total of 4,459 unique IGPs and 361 glycans from 758 glycoproteins. Remarkably, we identified 182 upregulated IGPs from 67 proteins (p<0.05, FC>1.50) and 108 downregulated IGPs from 44 proteins (p<0.05, FC<0.67) in the NAFLD group. Among these, we highlighted an essential acute phase glycoprotein, alpha-1-acid glycoprotein 1 (A1TA), which is synthesized in the liver and plays a significant role in the NAFLD progression. Besides, the complex-type, fucosylation-type and sialylation-type N-glycans were upregulated significantly in NAFLD group (p<0.001, t-test). These differentially expressed N-glycosylation modifications provide important clues for the diagnosis and pathogenesis of NAFLD.

2024-07-04 | PXD053626 |

Precision mapping of glycosite-specific glycans reveals distinctive N-glycosylation on human spermatozoa

Project description:In this study, we applied the recently developed software, StrucGP to large-scale characterize glycoproteins, and IGPs, as well as precise site-specific glycan structures in human spermatozoa. Furthermore, bioinformatical analyses were conducted to systematically describe the potential functions of N-glycosylation in human spermatozoa.

2022-05-19 | PXD026649 | Pride

Characterization of kidney-specific and site-specific N-glycosylation signatures of isolated uromodulin from human urine

Project description:Uromodulin (Umod, Tamm–Horsfall protein), as the most abundant urinary N-glycoprotein exclusively produced by the kidney, can form filaments to antagonize the adhesion of uropathogens. However, the kidney-specific and site-specific N-glycosylation signatures of this glycoprotein remain poorly understood due to the lack of suitable isolated and analytical methods.

2023-05-11 | PXD041640 |

Site-specific glycosylation mapping of Fc gamma receptor IIIb from neutrophils of individual healthy donors

Project description:The uploaded dateset corresponds to MS1 and MS2 spectra obtained for Fc gamma receptor IIIb isolated from neutrophils of individual healthy donors. They represent NA1/NA2, NA2/NA2, NA2/NA2 allotype respectively. Based on the data, the targeted analysis of the N-glycosylation has been performed for the article: Wojcik et. al, Site-specific glycosylation mapping of Fc gamma receptor IIIb from neutrophils of individual healthy donors.

2020-08-05 | MSV000085913 | MassIVE

Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a ‘liquid gold’ biopsy

Project description:Background: Biomarkers that reflect glioblastoma tumour activity and treatment response are urgently needed to help guide clinical management, particularly for recurrent disease. As the urinary system is a major clearance route of circulating extracellular vesicles (EVs; 30-1000 nm nanoparticles) we explored whether sampling urinary-EVs could serve as a simple and non-invasive liquid biopsy approach for measuring glioblastoma-associated biomarkers. Methods: Fifty urine specimens (15-60 ml) were collected from 24 catheterised glioblastoma patients immediately prior to primary (n=17) and recurrence (n=7) surgeries, following gross total resection (n=9), and from age/gender-matched healthy participants (n=14). EVs isolated by differential ultracentrifugation were characterised and extracted proteomes were analysed by high-resolution data-independent acquisition liquid chromatography tandem mass spectrometry (DIA-LC-MS/MS). Results: Overall, 6857 proteins were confidently identified in urinary-EVs (q-value≤0.01), including 94 EV marker proteins. Glioblastoma-specific proteomic signatures were determined, and putative urinary-EV biomarkers corresponding to tumour burden and recurrence were identified (FC≥|2|, adjust p-val≤0.05, AUC>0.9). Conclusion: In-depth DIA-LC-MS/MS characterisation of urinary-EVs substantiates urine as a viable source of glioblastoma biomarkers. The promising ‘liquid gold’ biomarker panels described here warrant further investigation.

2024-04-18 | PXD046511 | Pride

Urinary proteomics in youths with and without type 1 diabetes

Project description:Diabetic kidney disease is the leading cause of end-stage renal disease worldwide. Our understanding of the early kidney response to chronic hyperglycemia remains incomplete. In this study, we aimed to uncover the early, dysregulated pathways in the diabetic kidney before the onset of microalbuminuria by analysing the urinary proteomes of otherwise healthy youths with and without type 1 diabetes. Our study population included two cohorts for the discovery (N = 30) and validation (N = 30) of differentially excreted proteins. Of the 2451 proteins identified, 576 were quantified in all samples from the discovery cohort, and 34 comprised the urinary signature for early type 1 diabetes after Benjamini-Hochberg adjustment (Q < 0.05). The top pathways associated with this signature included lysosome, glycosaminoglycan degradation, and innate immune system (Q < 0.01). Notably, all enzymes involved in keratan sulfate degradation were significantly elevated in urines from youths with type 1 diabetes (fold change > 1.6). Increased urinary excretion of monocyte differentiation antigen CD14, hexosaminidase A, and lumican was also observed in the validation cohort (P < 0.05). Our findings draw attention to novel pathways such as keratan sulfate degradation in the early kidney response to hyperglycemia.

2020-06-01 | PXD017213 | Pride

Integrated proteomics and N-glycoproteomic characterization of glioblastoma multiform revealed N-glycosylation heterogeneities and elevations in mannose, sialyation and fucosylation

Project description:Glioblastoma multiforme (GBM) is a highly malignant primary brain tumor. While tremendous efforts in multi-omics research to profile the dysregulated molecular mechanisms and cellular pathways of the disease have been exerted, the glycoproteomics of GBM remains incompletely understood. Glycosylation, as one of the most important post-translational modifications, is crucial in regulating cell proliferation and relevant oncogenic pathways. In this study, we systematically profiled the N-glycoproteomics of para-cancerous and cancerous tissues from GBM patients to reveal site-specific N-glycosylation patterns defined by intact glycopeptides (IGPs). A total of 1863 distinct IGPs with 161 N-linked glycan compositions and 326 glycosites were identified and quantified. We then discovered that 396 IGPs from 43 glycoproteins differed between adjacent and GBM tissues. A more in-depth characterization of the enriched functions of differentially expressed glycopeptides was performed. Thereafter, the proteomics and glycoproteomics data were combined, and the proportion of normalized glycosylation alterations was calculated to determine whether the difference in expression of glycopeptides could be attributed to global protein levels or glycosylation. Alterations in glycosylation triggered by site-specific N-glycans and glycoprotein abundance, as well as glycosite heterogeneity, were demonstrated. Ultimately, examination of the overall glycosylation levels revealed the positive contribution of oligo-mannose resulting from altered glycol-enzyme expression levels, along with aberrant complex glycans caused by increased sialylated or/and fucosylated glycans. Overall, the dataset highlights N-glycosylation heterogeneities and altered glycans at post-translational levels and provides valuable information for novel therapeutic approaches and specific detection strategies.

2021-11-26 | PXD029920 |

LC-MS/MS data for HCA mRNA antibodies

Project description:Fc N-glycosylation of IgGs is necessary for effector functions and is a crucial component of quality control. Fc N-glycan profiles of HCA produced by two platforms were determined using mass spectrometry which revealed major differences in site occupancy, glycan types, and glycoform distribution.

2024-05-22 | PXD047910 | Pride

LncRNA expression profiling for 9 human plasma samples from systemic lupus erythematosus patients and healthy controls

Project description:To screen the differentially expressed lncRNAs, we performed lncRNA profiling using ArrayStar Human LncRNA Microarray in 24 new-onset systemic lupus erythematosus (SLE) patients and 12 age- and sex-matched healthy controls (HCs). For the lncRNA microarray screening, total RNA from plasma was isolated from 12 SLE without nephritis, 12 lupus nephritis (LN) and 12 HCs. Four RNA samples were mixed togther as a pool of sample for microarray analysis. Accordingly, there were each three pooled RNA samples from 12 SLE without nephritis, 12 LN and 12 HCs for microarray analysis. Hierarchical clustering showed the plasma levels of lncRNAs and mRNAs differed significantly between 24 new-onset SLE patients and 12 control subjects. With a fold change ≥ 2 and P ≤ 0.05, we identified 1315 significantly differentially expressed lncRNAs (743 lncRNAs up-regulated and 572 lncRNAs down-regulated) and 1363 differentially expressed mRNAs (745 mRNAs up-regulated and 618 mRNAs down-regulated) in plasma of SLE patients compared with control samples.

2017-08-12 | GSE102547 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data